An interventional study of bone densitometric examination using REMS technology and questionnaires in Osteoporosis, Pregnancy and Twin Pregnancy, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to female participants aged 30 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Osteoporosis with a site in Italy — 21 open to participants now, 25 under way, none of them phase 3. Osteoporosis · Italy.
Among the 60 studies in Osteoporosis with a site in Italy, this one is the 20th largest by planned enrollment of the 35 interventional ones that give a count, is one of 6 that started in 2025, is one of 16 with no phase, reaches primary completion later than 16 of the 24 other live ones, and was the 56th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →21 of the 60 studies in Osteoporosis with a site in Italy are open now. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 5–18
Regina Elena Cancer Institute · Sites in Italy
Ages 35–70 · Women only
Istituto Auxologico Italiano · Sites in Italy
Ages 50+ · Women only
IRCCS San Raffaele · Sites in Italy
Ages 50+ · Men only
Istituto Ortopedico Rizzoli · Sites in Italy
Ages 40+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 30 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 15 · Phase 4 3
First in 2001; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 120 across the 35 interventional studies, 150 across the 25 observational. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 60 have an industry lead sponsor. The 10 most frequent:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 3 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Osteoporosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06551155Istituto Ortopedico RizzoliPeripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures | 2026-12-21 |
| NCT07508553Fondazione Policlinico Universitario Agostino Gemelli IRCCSComparison of Bone Mineral Density in the Third Trimester Between Women in Singleton and Twin Pregnancies Using Questionnaires and REMS Densitometric Examination | 2026-12-23 |
| NCT04730622Istituto Ortopedico RizzoliStudy of Parameters of Osteosarcopenia in Patients With Hip Fracture | 2026-12-31 |
| NCT07512453Azienda Ospedaliero, Universitaria PisanaStudy in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration of Anti-fracture Therapy | 2027-03-31 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 60 studies in Osteoporosis with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical study aims to monitor and evaluate bone mineral density and fracture risk in women with singleton and twin pregnancies through the combined use of:
Primary objective:
Secondary objectives:
Upon enrollment, gestational history, maternal clinical conditions, drug therapy, demographic and anthropometric parameters will be recorded, and specific questionnaires developed by the Fragility Fracture Observatory (OFF) will be administered. These questionnaires aim to assess all risk factors that could lead patients to have a fracture during pregnancy and to evaluate both dietary habits (specifying the type of food with high, medium and low calcium content with relative portions and frequencies) and adherence to the Mediterranean diet (determining, based on the total score, whether the dietary calcium intake is sufficient to support the physiological adaptation of the pregnant woman, who must provide adequate amounts of calcium for the development of the fetal skeleton and the correct growth of the newborn during breastfeeding).
The first questionnaire is divided into two sections: one specifically for "calcium intake" and the other dedicated to assessing the woman's eating habits (Predimed Questionnaire) during pregnancy, which measures portion sizes and the frequency of nutrient intake through food and beverages.
The second questionnaire, AFEF (Fracture Risk Algorithm for Women of Childbearing Age), specifically assesses fracture risk during pregnancy. It collects anthropometric information (weight and height), medical history and personal and family medical history, lifestyle (number of cigarettes smoked daily), and any therapies undertaken before and during pregnancy.
An assessment of bone health using ultrasound densitometry using REMS technology, integrated into the EchoStation device (Echolight Spa, Lecce, Italy), is performed during the third trimester checkup.
The importance of using REMS ultrasound lies in its complete absence of ionizing radiation, ease of use, and rapid scanning. Thanks to an innovative parameter called Fragility Score (FS), intrinsically correlated with bone quality and independent of BMD, REMS allows for the assessment of bone fragility and its resulting fracture risk, representing a useful diagnostic tool also in predicting the risk of fragility fractures. All of this makes this method absolutely compatible and optimal for routine monitoring of bone health and fracture risk in women during pregnancy.
The objectives of the REMS ultrasound technology are:
The EchoStation device (manufactured by Echolight Spa) consists of a medical-grade cart, which houses a panel PC, a medical-grade keyboard and mouse, a main unit, and a convex probe operating at a nominal frequency of 3.5 MHz. The EchoStudio software, integrated into the EchoStation device, dedicated to assessing bone health, allows for the automatic calculation of the same diagnostic parameters provided by a DEXA scan (Bone Mineral Density (BMD), T-score, and Z-score) from unfiltered ultrasound radiofrequency signals acquired during an ultrasound scan of a reference anatomical specimen (femoral neck). The ultrasound signals of the bone region in question are automatically processed and compared with reference spectral models previously derived from healthy and osteoporotic patients in order to assess the subject's bone mineral density; and with previously derived reference spectral models from patients with and without fractures to assess bone fragility and related fracture risk using the innovative FS parameter.
This approach, unlike conventional ultrasound, maximizes the information gathered from the acquired signals, while the reconstructed B-mode ultrasound images serve as a guide for the correct identification of the bone being examined. The simultaneous acquisition of multiple ultrasound signals for each frame is integrated with the ultrasound imaging, which also serves as a guide for identifying the region of interest (ROI) within the bone being examined, providing a solid and reliable statistical basis for subsequent analyses.
Women between the 35th and 41st week of gestation (inclusive) will undergo ultrasound examination of the proximal femur using an EchoStation ultrasound system (Echolight Spa, Lecce, Italy) with a convex probe operating at a nominal frequency of 3.5 MHz. Trained operators will follow a standard procedure. Specifically, a 40-second software-guided ultrasound scan will be performed with the ultrasound probe positioned at the head-neck axis of the femur. The probe will be positioned parallel to the long axis of the femur, and the transducer focus and scan depth will be appropriately set to place the femoral neck interface in the focal zone of the beam and in the central portion of the image. The software will then automatically analyze the unfiltered ultrasound signals, identifying the bone interface and ROI; the resulting signals will be processed and, after this automatic process, the diagnostic report will be produced.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
EXCLUSION CRITERIA
Patients will not be included in the study if at least one of the following exclusion criteria is met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women in physiological pregnancy between the 35th and 41st week, with a single pregnancy
Device: bone densitometric examination using REMS technology · Other: questionnaires
Women in physiological pregnancy between the 35th and 41st week, with a single pregnancy
Device: bone densitometric examination using REMS technology · Other: questionnaires
An assessment of bone health using ultrasound densitometry using REMS technology, integrated into the EchoStation device (Echolight Spa, Lecce, Italy), is performed during the third trimester check-up. Thanks to an innovative parameter called Fragility Score (FS), intrinsically correlated with bone quality and independent of BMD, REMS allows assessment of bone fragility and its resulting fracture risk, representing a useful diagnostic tool also in predicting the risk of fragility fractures.
Specific questionnaires developed by the Fragility Fracture Observatory (OFF) will be administered. Their purpose is to assess all risk factors that could lead to fractures during pregnancy, as well as to evaluate both dietary habits and adherence to the Mediterranean diet
BMD differences between singleton and twin pregnancies
To identify, in the third trimester of pregnancy (between the 35th and 41st gestational week), any differences in bone mineral density (BMD) between women with a singleton pregnancy and women with dichorionic and monochorionic twin pregnancies.
Time frame: From enrollment through delivery, an average of six weeks
BMD values and maternal clinical parameter
Evaluation of the correlation between bone mineral density (BMD), measured by dual-energy X-ray absorptiometry (DEXA) and expressed in g/cm², and the following maternal clinical parameters: body mass index (BMI, kg/m²) maternal age (years) weight gain during pregnancy (kg) The correlation will be analyzed using a correlation coefficient (Pearson or Spearman, depending on the data distribution).
Time frame: From enrollment through delivery, an average of six weeks
Correlation between bone mineral density (DEXA, g/cm²) and validated questionnaire scores (calcium intake, PREDIMED, AFEF)
Evaluation of the correlation between bone mineral density (BMD) values, measured by dual-energy X-ray absorptiometry (DEXA) and expressed in g/cm², and: * daily dietary calcium intake, assessed using a dedicated questionnaire and expressed in mg/day * adherence to the Mediterranean diet, assessed using the PREDIMED questionnaire and expressed as a total score * individual risk, assessed using the AFEF questionnaire and expressed as a total score The correlation will be analyzed using a correlation coefficient (Pearson or Spearman, depending on the data distribution)
Time frame: From enrollment through delivery, an average of six weeks
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 220 non-industry interventional studies with no phase under Osteoporosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's planned 12 months is below that.
Counting every sponsor, half of 239 studies reached it within 26 months; a quarter within 9 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS →